European drug regulator investigating suicidal thoughts among some weight-loss jab users

Suicidal behaviour is not currently listed as a side-effect in the EU product information of these medicines

The drugs help to conrol appetite (Alamy/PA)

Europe’s drug regulator is investigating the risk of suicidal thoughts and thoughts of self-harm in patients using some weight loss and diabetes jabs.

The European Medicines Agency’s (EMA) safety committee said it is looking at cases among people who use a semaglutide or liraglutide-containing medicine for weight loss.